CRISPR Therapeutics (NasdaqGM:CRSP) Sees 12% Weekly Dip Following COO Resignation

CRISPR Therapeutics experienced an 12% price decline over the last week, coinciding with significant market disruption driven by escalating tariff tensions, which saw the S&P 500 and Nasdaq drop 10% and 11%, respectively. The recent announcement of the COO’s resignation was likely a contributing factor to the decline, adding uncertainty around the company’s strategic direction. The broader market sell-off amid global trade uncertainties intensified pressure on the company, as well as on other biotechnology stocks. Despite these challenges, CRISPR’s performance remains closely aligned with the overall market turbulence highlighted by a substantial downturn in major indices.

Buy, Hold or Sell CRISPR Therapeutics? View our complete analysis and fair value estimate and you decide.

The end of cancer? These 21 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer’s.

Over the past five years, CRISPR Therapeutics (NasdaqGM:CRSP) saw a total shareholder return of 28.63% decline. Earnings volatility has been a significant factor, particularly in 2024, where the full year revenue dropped to US$37.31 million from US$371.21 million the previous year, coupled with a net loss increase to US$366.25 million from US$153.61 million. The underperformance relative to the US Biotechs industry, which itself fell 14.8% over the last year, adds context to the company’s challenges in navigating profitability improvements.

Furthermore, product-related developments offered a mixed impact. Despite the positive FDA approval of CASGEVY, the first CRISPR-based therapy, in December 2023, the financial pressures continued amidst executive shifts, such as the departure of COO Julianne Bruno in March 2025. Finally, clinical trial setbacks, like reduced revenue from Phase 1/2 trials as announced in December 2024, also contributed to the subdued returns over this period.

Examine CRISPR Therapeutics’ earnings growth report to understand how analysts expect it to perform.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.